IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 250 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,293,670 | -54.1% | 2,482,125 | -29.0% | 0.00% | -50.0% |
| Q2 2023 | $24,623,160 | -47.6% | 3,497,608 | -54.5% | 0.00% | -60.0% |
| Q1 2023 | $47,002,342 | +48.0% | 7,692,691 | +54.8% | 0.01% | +25.0% |
| Q4 2022 | $31,757,462 | +216.3% | 4,969,869 | +374.2% | 0.00% | +300.0% |
| Q3 2022 | $10,040,000 | -37.3% | 1,048,000 | -27.7% | 0.00% | -50.0% |
| Q2 2022 | $16,008,000 | +72.1% | 1,450,057 | +159.5% | 0.00% | +100.0% |
| Q1 2022 | $9,302,000 | +92.2% | 558,750 | +120.3% | 0.00% | 0.0% |
| Q4 2021 | $4,841,000 | -38.4% | 253,575 | -20.5% | 0.00% | 0.0% |
| Q3 2021 | $7,863,000 | +26.1% | 318,859 | +33.1% | 0.00% | 0.0% |
| Q2 2021 | $6,235,000 | -64.4% | 239,597 | -56.7% | 0.00% | -66.7% |
| Q1 2021 | $17,517,000 | +99.0% | 553,314 | +191.8% | 0.00% | +200.0% |
| Q4 2020 | $8,801,000 | +146.9% | 189,653 | +75.1% | 0.00% | 0.0% |
| Q3 2020 | $3,565,000 | -15.7% | 108,285 | -29.7% | 0.00% | 0.0% |
| Q2 2020 | $4,227,000 | +40.0% | 153,982 | +52.7% | 0.00% | 0.0% |
| Q1 2020 | $3,020,000 | -42.3% | 100,858 | -46.6% | 0.00% | 0.0% |
| Q4 2019 | $5,230,000 | -2.1% | 188,930 | -35.6% | 0.00% | 0.0% |
| Q3 2019 | $5,344,000 | +484.0% | 293,567 | +686.7% | 0.00% | – |
| Q2 2019 | $915,000 | +5.2% | 37,318 | -59.2% | 0.00% | – |
| Q1 2019 | $870,000 | -56.3% | 91,508 | -59.3% | 0.00% | -100.0% |
| Q4 2018 | $1,990,000 | +17.9% | 224,873 | +49.8% | 0.00% | – |
| Q3 2018 | $1,688,000 | -50.8% | 150,092 | -44.0% | 0.00% | -100.0% |
| Q2 2018 | $3,430,000 | +26.9% | 267,955 | +67.5% | 0.00% | 0.0% |
| Q1 2018 | $2,703,000 | +166.8% | 159,959 | +26.3% | 0.00% | – |
| Q4 2017 | $1,013,000 | +52.1% | 126,682 | +47.5% | 0.00% | – |
| Q3 2017 | $666,000 | +78.6% | 85,875 | +69.4% | 0.00% | – |
| Q2 2017 | $373,000 | – | 50,702 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |